Aspire Biopharma Holdings, Inc. (ASBPW)

Quarterly Report Filed: 2026-05-15

Key Insights

The filing contains primarily structural XML metadata without substantive financial data, making it impossible to assess Q1 2026 revenue trends, operating results, or margin performance.
Multiple related-party transactions are documented including loan agreements with affiliates (Apogee Pharma, SSVK Associates LLC, Jinal Sheth) and securities purchase agreements, suggesting significant reliance on insider financing rather than traditional capital markets.
The company appears to be in early-stage operations with multiple convertible preferred stock issuances, warrant exercises, and ELOC (Equipment Line of Credit) agreements, indicating cash burn and ongoing dilution concerns for common shareholders.
Subsequent events references suggest material developments occurred post-quarter end (January and May 2026), but the actual nature and financial impact of these events are not disclosed in the provided content.

Current Report Filed: 2026-05-14

Key Insights

Aspire Biopharma executed a 1-for-30 reverse stock split effective May 11, 2026, which typically indicates the company was below Nasdaq minimum bid price requirements and needed to regain compliance.
The reverse split automatically combines shareholder holdings without new fractional shares being issued, with fractional shares rounded up to the nearest whole share, potentially diluting existing shareholders slightly.
The company's CUSIP number changed to 738920305 post-split while the trading symbol remains 'ASBP', allowing the company to continue trading on Nasdaq Stock Market LLC after the restructuring.
As an emerging growth company, Aspire Biopharma has regulatory flexibility, but the reverse split signals potential financial or operational challenges that required structural action rather than organic recovery.

Current Report Filed: 2026-04-16

Key Insights

Aspire Biopharma Holdings, Inc. (ASBPW) is an emerging growth company, indicating potential for high-growth prospects but also higher risk.
The company has changed its name from PowerUp Acquisition Corp., signaling a transition in its business focus.
Aspire Biopharma is now publicly traded on the Nasdaq exchange, providing access to capital markets for future growth.

Current Report Filed: 2026-04-16

Key Insights

Aspire Biopharma Holdings is seeking to effect a reverse stock split in the range of 1-for-5 to 1-for-500, with the exact ratio to be determined by the Board.
The company is seeking shareholder approval to issue shares of common stock upon conversion of Series A Convertible Preferred Stock, including in excess of 19.99% of the outstanding shares.
Shareholders are also being asked to approve the issuance of 19.99% or more of the company's outstanding common stock pursuant to an Equity Line of Credit (ELOC) agreement.

Current Report Filed: 2026-04-16

Key Insights

Aspire Biopharma Holdings, Inc. (ASBPW) completed a $21 million private placement of Series A Convertible Preferred Stock, including the conversion of $943,801 in existing debt.
The company obtained shareholder approval for the conversion of the preferred shares in excess of 19.99% of outstanding common stock.
As a result of the offering, the company believes it now meets the minimum stockholders' equity requirement for continued listing on the Nasdaq Capital Market.

Current Report Filed: 2026-04-15

Key Insights

Aspire Biopharma Holdings is acquiring the Driver Controls Systems business unit of Firefish Topco, LLC for $30 million on a cash-free, debt-free basis.
The acquisition will be funded with cash on hand, and the company plans to engage Lakewood & Company to provide management services for the acquired business.
The letter of intent includes provisions for break-up fees, exclusivity, and confidentiality, but the transaction remains subject to the negotiation and execution of a definitive purchase agreement.

Current Report Filed: 2026-02-12

Key Insights

Aspire Biopharma Holdings raised $11 million through a private placement of Series A Convertible Preferred Stock, which can be converted into common shares at a discounted price.
The company will use the proceeds to fund operations and plans a second closing of up to $10 million in additional preferred stock, contingent on shareholder approval and registration of the underlying common shares.
The preferred stock conversion is subject to a 19.99% ownership cap, requiring shareholder approval to exceed this limit, which could provide an overhang on the common stock.

Current Report Filed: 2026-02-06

Key Insights

Aspire Biopharma filed a Form 8-K related to the designation of 25,000 shares of Series A Convertible Preferred Stock, which has a conversion price at 80% of the lowest closing price of the common stock over the prior 5 trading days.
The Series A Preferred Stock will rank senior to the common stock and have certain liquidation preferences, allowing holders to receive payouts prior to common shareholders.
The Preferred Stock has a conversion cap that limits holders from owning more than 4.99% of the outstanding common shares, unless shareholder approval is obtained to exceed 19.99%.

Current Report Filed: 2026-01-30

Key Insights

Aspire Biopharma has secured a $2 million debenture financing, which it plans to use to pay off debt and for working capital purposes.
The debentures have a short maturity of 90 days or upon the company's receipt of $8 million in any equity or debt financing, indicating near-term liquidity needs.
As an emerging growth company, Aspire may have flexibility in financial reporting standards, which could impact transparency and comparability for investors.

Current Report Filed: 2026-01-15

Key Insights

Aspire Biopharma Holdings, Inc. has approved a new stock incentive plan that allows the company to grant equity awards to employees, directors, and consultants with the goal of attracting, retaining, and motivating key contributors.
The company has also approved specific forms of award agreements for restricted stock units and stock options to be used for equity grants under the new plan.
As an emerging growth company, Aspire Biopharma has elected not to use the extended transition period for complying with new or revised financial accounting standards.

Current Report Filed: 2026-01-13

Key Insights

Director Surendra Ajjarapu has resigned from the company's Board of Directors, effective immediately. This appears to be a voluntary departure not due to any disagreement.
The company is an emerging growth company, which means it may take advantage of certain exemptions from financial reporting and other requirements.
The company's common stock and warrants are publicly traded on the Nasdaq stock exchange.

Current Report Filed: 2026-01-06

Key Insights

Aspire Biopharma Holdings, Inc. is exchanging approximately $1.75 million in debt for shares of its common stock, which may help improve its balance sheet and financial position.
The exchange agreements allow the debt holders to convert their debt into common stock at a discount to the current market price, providing them an incentive to participate.
The company may also be able to repay a portion of the remaining debt if it secures a financing of over $3 million, which could further improve its financial flexibility.

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Important Information